ASX:TLX
ASX:TLXBiotechs

Telix Pharmaceuticals (ASX:TLX) Is Down 15.9% After Reaffirming 2025 Revenue Outlook and Increased R&D Spend

On July 22, 2025, Telix Pharmaceuticals confirmed its revenue guidance for fiscal year 2025 at A$770 million to A$800 million, driven by ongoing Illuccix sales and 11 months of contributions from its RLS acquisition, while also projecting a 20% to 25% increase in R&D expenditures over the previous year. This reaffirmed outlook highlights Telix's focus on balancing robust commercial operations with sizable investment in future research initiatives. We’ll explore how Telix’s increased R&D...
ASX:MP1
ASX:MP1IT

Megaport and DartPoints Partnership Could Be a Game Changer for Megaport (ASX:MP1)

Earlier this month, Megaport and DartPoints announced a partnership to bring Megaport's cloud connectivity platform to DartPoints' Greenville Data Center, marking Megaport’s first presence in South Carolina and opening access to over 975 data centers and 380-plus cloud onramps across the region. This collaboration allows regional enterprises to provision private cloud connections with reduced latency and lower bandwidth costs, positioning Greenville as a key Southeast hub for hybrid cloud...
ASX:CRD
ASX:CRDOil and Gas

ASX Penny Stocks To Watch In July 2025

As the Australian market faces a slight downturn, with ASX 200 futures indicating a dip, investors are keeping a close eye on opportunities that can weather economic uncertainties. Penny stocks, despite their somewhat outdated moniker, continue to attract attention for their potential value and growth prospects. By focusing on those with solid financials and clear growth potential, investors may uncover promising opportunities among smaller or newer companies.